Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Profit After Tax (2020 - 2025)

Barinthus Biotherapeutics' Profit After Tax history spans 6 years, with the latest figure at -$11.1 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 46.09% year-over-year to -$11.1 million; the TTM value through Dec 2025 reached -$66.4 million, down 8.69%, while the annual FY2025 figure was -$66.4 million, 8.77% down from the prior year.
  • Profit After Tax reached -$11.1 million in Q4 2025 per BRNS's latest filing, up from -$14.6 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $15.7 million in Q2 2022 to a low of -$23.8 million in Q2 2023.
  • Average Profit After Tax over 5 years is -$12.3 million, with a median of -$15.5 million recorded in 2021.
  • Peak YoY movement for Profit After Tax: tumbled 2984.18% in 2021, then surged 280.4% in 2022.
  • A 5-year view of Profit After Tax shows it stood at -$15.4 million in 2021, then crashed by 37.78% to -$21.2 million in 2022, then increased by 18.77% to -$17.2 million in 2023, then decreased by 19.49% to -$20.5 million in 2024, then soared by 46.09% to -$11.1 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Profit After Tax are -$11.1 million (Q4 2025), -$14.6 million (Q3 2025), and -$21.1 million (Q2 2025).